登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1.本次股东大会未出现否决议案的情形； 2.本次股东大会未涉及变更前次股东大会决议事项。 一、会议召开情况 1.会议召开时间： 现场会议时间：2025年5月19日下午15：00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月19日上午9:15- 9:25、9:30-11:30，下午13:00-15:00期间任意时间；通过深圳证券交易所互联网投票系统投票的具体时 间为2025年5月19日9:15-15:00期间任意时间。 2.现场会议召开地点：公司会议室（成都市青羊区百花西路36号） 3.会议召开方式：现场表决与网络投票相结合 4.会议召集人：公司董事会 5.会议主持人：刘革新先生 本次股东大会的召集、召开和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的相关规定。 二、会议出席情况 1.出席公司本次会议的股东及股东代理人共计359名，代表股份694,923,966股，占公司有表决权股份总 数的43. ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-040 2.现场会议召开地点：公司会议室（成都市青羊区百花西路36号） 四川科伦药业股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 3.会议召开方式：现场表决与网络投票相结合 特别提示： 1.本次股东大会未出现否决议案的情形； 2.本次股东大会未涉及变更前次股东大会决议事项。 一、会议召开情况 1.会议召开时间： 现场会议时间：2025年5月19日下午15：00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年5月19日上午9:15-9:25、9:30-11:30，下午13:00-15:00期间任意时间；通过 深圳证券交易所互联网投票系统投票的具体时间为2025年5月19日9:15-15:00期 间任意时间。 4.会议召集人：公司董事会 5.会议主持人：刘革新先生 本次股东大会的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定。 二、会议出席情况 1.出席公司本次会议的股东及股东代理 ...

法律意见书 北京中伦（成都）律师事务所 关于四川科伦药业股份有限公司 2024 年年度股东大会的 法律意见书 致：四川科伦药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会《上市 公司股东会规则》、《深圳证券交易所上市公司股东会网络投票实施细则》等法 律、法规及规范性文件的规定，北京中伦（成都）律师事务所（以下简称"中伦" 或"本所"）指派律师出席了四川科伦药业股份有限公司（以下简称"公司"或 "科伦药业"）2024 年年度股东大会（以下简称"本次股东大会"），并对本次 股东大会的相关事项进行见证。 本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以前已 经发生或者存在的事实，严格履行了法定职责，遵循勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、完整，所 发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并 承担相应法律责任。 为出具本法律意见书，本所律师审查了公司提供 ...

广告片一经发布就在各大平台快速传播，这不仅是因为75岁董事长赤膊上阵带来的视觉冲击，还因为这是医药圈第一个企业家IP。业界关心，流量带货逻辑 在医药圈能走通吗？刘革新个人IP能否撬动产品快速变现，并带领科伦旗下的大健康公司走向成功？ 健硕的胸肌、紧实的背部线条、清晰可见的腹肌……科伦药业（002422.SZ）董事长刘革新近日在广告片中大秀身材，这位75岁的企业家，在用自己的身体 为抗衰产品代言，开启第四次创业征程。 企业家要做个人IP，多少得有些人格光环。除了泰森般的躯体，刘革新还有一副不错的歌喉，他喜欢男声独唱，其独唱《星》《在路上》的视频这两天也见 诸科伦旗下各平台。刘革新还是一名学霸，他告诉经济观察报，他的高考作文差一分满分。他在商界纵横捭阖，目前拥有三家上市公司——科伦药业、科伦 博泰（06990.HK）、川宁生物（301301.SZ），因为最早创立的科伦药业稳坐大输液领域的头把交椅，刘革新在医药行业有"输液大王"之称。 不过，相比于汽车圈的马斯克、雷军，快消圈的于东来，送外卖的刘强东……医药圈大佬刘革新的人格化特点还不突出，人设不够清晰，目前营销团队放出 的物料仍缺乏娱乐化、场景化的表达，难以突破医 ...

Core Viewpoint - The advertisement featuring the 75-year-old chairman of Kelun Pharmaceutical, Liu Gexin, showcasing his muscular physique has sparked discussions about the authenticity of the advertisement, the efficacy of the endorsed product, and the development of the anti-aging industry [2][3]. Group 1: Advertisement Impact - The advertisement represents a bold and innovative attempt to capture attention in a traffic-driven era, leveraging Liu's impressive physique to convey a positive message about health and vitality at an older age [2]. - Liu's display of health challenges the notion that age is a barrier to pursuing a healthy lifestyle, serving as an inspirational example for younger generations [2]. Group 2: Product Pricing and Market Demand - The endorsed product, Ergothioneine capsules, priced at 1499 yuan for 60 capsules, raises concerns about its value proposition, especially since it is more expensive in China than in Japan [3]. - Despite the high price, the anti-aging product market is growing due to the increasing demand driven by an aging population, indicating a significant market potential [3]. Group 3: Industry Challenges - There is currently no widely recognized anti-aging product with proven efficacy, leading to a proliferation of exaggerated claims and false advertising in the market [3][4]. - The anti-aging industry requires substantial technological innovation and research investment to advance, emphasizing the need for companies to focus on improving product quality and efficacy [4]. Group 4: Consumer Education and Expectations - The anti-aging sector must prioritize consumer education to combat misinformation and enhance understanding of product capabilities, while also managing consumer expectations regarding the efficacy of these products [4][5]. - The advertisement serves as a deeper discussion about health, aging, and entrepreneurial spirit, highlighting the importance of product effectiveness beyond mere promotional tactics [4].

Core Insights - The healthcare industry is increasingly shifting towards consumer health and wellness sectors, with companies like Kelun Pharmaceutical entering the market to diversify their revenue streams amid declining traditional business performance [1][6][7] - The demand for stem cell therapy is rapidly growing in China, with some treatments costing up to 1 million yuan, leading to significant profits for service providers [1][3] - The aesthetic medicine sector is witnessing a surge in new registrations, with nearly 10,000 new medical beauty-related companies registered in early 2023, indicating a trend of traditional pharmaceutical companies pivoting to this area for survival [3][4] Company Strategies - Kelun Pharmaceutical's chairman has publicly stated the company's commitment to the health and wellness sector, highlighting the need for diversification due to intense competition in traditional medical fields [1][6] - Many companies are forming new entities or acquiring existing firms to enter the aesthetic medicine market, leveraging their traditional business strengths in production or marketing [3][4] - Companies like Chuaning Bio, previously focused on antibiotic intermediates, are now developing anti-aging products, although their contribution to revenue remains minimal at this stage [7] Financial Performance - Kelun Pharmaceutical reported a 30% decline in revenue and a 43% drop in net profit in Q1 2025, prompting a focus on anti-aging products [6] - Four环医药's aesthetic medicine segment generated approximately 323 million yuan in revenue in the first half of 2024, a 66.4% increase year-on-year, contributing significantly to the company's overall income [8] - Companies in the biological materials sector, such as Guanhao Bio, are also seeing growth in cell technology services, with related revenues exceeding 10% of total income [8] Regulatory Environment - Recent regulatory guidelines from the National Medical Products Administration are clarifying the direction for the commercialization of cell therapies, emphasizing the need for a robust management system to ensure safety [9] - The aesthetic medicine field is currently seen as a simpler entry point for regenerative medicine technologies, although many practices may not meet the rigorous standards of true regenerative medicine [5][9]

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is experiencing continuous breakthroughs in innovative drugs and synthetic biology commercialization, indicating an upward turning point in operations and performance driven by innovation, with potential valuation uplift from ongoing global clinical data for SKB264 [1][5] - The first quarter of 2025 showed significant revenue and profit declines primarily due to high base effects from the previous year and price fluctuations [1][2] Financial Performance - In 2024, the company achieved revenue of 21.812 billion yuan (YOY +1.67%) and a net profit of 2.936 billion yuan (YOY +19.53%) [1][11] - For Q1 2025, revenue was 4.390 billion yuan (YOY -29.42%) and net profit was 0.584 billion yuan (YOY -43.07%) [1][11] Business Segmentation - The intravenous infusion segment saw a revenue decline to 8.912 billion yuan in 2024 (YOY -11.85%), while the sales volume was 4.347 billion bags/bottles (YOY -0.70%) [2] - Non-infusion pharmaceuticals generated revenue of 4.169 billion yuan in 2024 (YOY +5.41%), with significant contributions from the plastic water needle business [3] - The intermediates and raw materials segment reported revenue of 5.856 billion yuan in 2024 (YOY +20.90%), driven by various antibiotic intermediates [4] Innovation and Commercialization - The company has over 30 projects in development, with several innovative drugs like SKB264 and A167 successfully approved in China, indicating a shift towards accelerated commercialization [5] - The internationalization efforts for SKB264 are expected to yield significant milestones, with potential revenue exceeding 1.2 billion USD from overseas licensing agreements [5] Earnings Forecast and Valuation - EPS estimates for 2025-2027 are projected at 1.88, 2.11, and 2.54 yuan respectively, with a PE ratio of 19 times based on the closing price on May 15, 2025 [11][13] - The company is expected to benefit from its innovative drug technology platform and synthetic biology platform, contributing to sustainable performance growth [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to see an upward turning point in operations and performance driven by innovation, particularly with the ongoing global clinical data readouts for SKB264, which may enhance valuation opportunities [1][5] - The first quarter of 2025 showed a significant decline in revenue and profit, primarily due to high base effects from the previous year and price fluctuations [1][2] Financial Performance Summary - In 2024, the company achieved revenue of 21.812 billion yuan (YOY +1.67%) and a net profit of 2.936 billion yuan (YOY +19.53%) [1][13] - For Q1 2025, the company reported revenue of 4.390 billion yuan (YOY -29.42%) and a net profit of 0.584 billion yuan (YOY -43.07%) [1][13] Business Segmentation Summary - The infusion segment experienced a revenue decline to 8.912 billion yuan in 2024 (YOY -11.85%), while the sales volume was 4.347 billion bags/bottles (YOY -0.70%) [2] - Non-infusion pharmaceuticals saw a revenue increase to 4.169 billion yuan in 2024 (YOY +5.41%), driven by the sales of innovative drugs [3] - The intermediates and raw materials segment achieved revenue of 5.856 billion yuan in 2024 (YOY +20.90%), with significant contributions from various antibiotic intermediates [4] Innovation and Commercialization - The company has a robust pipeline with over 30 projects, focusing on oncology, and several innovative drugs have been approved for market entry [5] - The internationalization efforts are highlighted by the overseas licensing of SKB264, with a total development and sales milestone exceeding 1.2 billion USD [5] Earnings Forecast and Valuation - The projected EPS for 2025-2027 is 1.88, 2.11, and 2.54 yuan respectively, with a PE ratio of 19 times based on the closing price on May 15, 2025 [11][13] - The company is expected to benefit from its innovative drug technology platform and cost reduction strategies in the intermediates and raw materials segment [11]

瑞财经 刘治颖 近日，科伦药业发布了一则视频广告，公司董事长刘革新硬核出圈。 视频显示，75岁董事长刘革新赤膊出镜，展示健硕肌肉，为旗下抗衰老产品"麦角硫因胶囊"代言。画面配以"刘先生75 岁，'没有不可能'"的广告词。 据媒体报道，科伦药业证券部工作人员表示，公司董事长一直在吃这款麦角硫因胶囊，视频没有进行后期修饰，董事长 长期自律并且每天早上5点会健身。 根据视频号提供的小程序，麦角硫因胶囊在售版本定价1499元/瓶(60粒)，每粒含30mg(毫克)麦角硫因。产品宣传称 其"清除自由基效果远超传统成分VC与辅酶Q10的10至30倍"，由"科伦永年携手日本老牌药企强强联合推出"。 | V | 0 | | --- | --- | | 分享 | 收藏 | 值得一提的是，在5月6日举行的业绩会中，刘革新就曾表示："董事会决心在未来三至五年的时间内实现治疗医学和预 防医学并驾齐驱的格局，科伦麦角硫因的广告词已经通过审查，不日即将播出，我出任该产品的代言人。" 刘革新，1951年出生，中国国籍，无境外居留权。科伦药业董事长，重庆医科大学优秀校友，研究生学历，高级工程 师。2023年4月，出任中共四川省经济和信息化行业 ...